Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Selcia Appoints New Director of Discovery

Published: Wednesday, October 09, 2013
Last Updated: Wednesday, October 09, 2013
Bookmark and Share
Appointment of John Davis to the role of Director of Discovery.

Selcia Limited has appointed John Davis to the newly created role of Director of Discovery.

John joins Selcia from Convergence Pharmaceuticals, where he served as Head of Biology between 2010 and 2013 and was a co-founder of the company.

Dr. Hans Fliri, chairman and CEO of Selcia Ltd., said “We are delighted that John has joined Selcia, his extensive drug discovery expertise will be a tremendous asset to our business. We have an ambitious plan to grow and further develop Selcia’s integrated drug discovery service. John’s knowledge of the international pharmaceutical and biotechnology industries will undoubtedly help us achieve that goal.”

John’s particular research interests have been focussed on cardiovascular, oncology and CNS disorders. Much of his 20 years’ drug discovery experience was gained at SmithKline Beecham and GlaxoSmithKline and encompasses a range of target classes including ion channels, GPCRs, kinases and proteases.

With his deep experience of target identification through to clinical proof of concept, John has been responsible for the discovery of 11 small molecule and biologic development candidates, and the preclinical pharmacology supporting two assets achieving positive Phase II and one product.

At GSK John was variously director of neurodegeneration research, a director of discovery technologies and director of biology for pain and epilepsy research, and was also instrumental in the formation and management of several large collaborations with universities.

John originally trained as a biochemist and has a PhD from Cambridge University. He was a research fellow at the Ludwig Institute for Cancer Research and Salk Institute for six years before joining SmithKline Beecham in 1993. He has over 100 peer reviewed publications and patents to his name.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Simon Bury Joins Selcia
Selcia Limited announces the appointment of Simon Bury as Business Development Director of its Discovery division, to lead expansion plans in its drug discovery offering.
Friday, June 03, 2011
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos